This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
by Kinjel Shah
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
by Zacks Equity Research
TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
Company News for Jul 26, 2024
by Zacks Equity Research
Companies In The News Are: ABBV, VLO, NOC, LUV.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Lies in Store for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
Q2 Earnings in Full Swing This week
by Zacks Equity Research
Q2 Earnings in Full Swing This week.
First Full Week of Q2 Earnings, PCE Out Friday
by Mark Vickery
No fewer than 845 companies are scheduled to report this week, including Alphabet (GOOGL) and Tesla (TSLA) Tuesday.
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.
Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.